Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyProlactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent mannerFAM83A confers EGFR-TKI resistance in breast cancer cells and in miceTrial watch - inhibiting PARP enzymes for anticancer therapyMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Activating HER2 mutations in HER2 gene amplification negative breast cancerMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivitySystematic identification of genomic markers of drug sensitivity in cancer cellsRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Antibody-based imaging of HER-2: moving into the clinic.Unnatural polyketide analogues selectively target the HER signaling pathway in human breast cancer cells.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataLapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repressionEstrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatmeAntitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer modelmRNA expression of DOK1-6 in human breast cancerIn vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.In silico modeling predicts drug sensitivity of patient-derived cancer cells.Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.Genome profiling of ERBB2-amplified breast cancers.Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmTargeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.Targeting the disordered C terminus of PTP1B with an allosteric inhibitorAn open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
P2860
Q21284978-09A506F3-45EB-4E6B-A115-7620D3BC8600Q21559661-71A2E6C9-481C-4AD8-A72C-9B2CF568789FQ24296333-ACB82F20-14B3-4946-84F1-0FEE3A05B279Q26745673-6BA57F5D-A030-449D-8451-C0FC95FF275AQ26772969-0914E3AB-2466-4C4C-9237-0598A62DFDE0Q26777681-97271CD9-5294-47EB-80DF-C05F9B6781BAQ26777733-A95202F4-ABB4-419C-8A5E-90B469972D5CQ26785612-0CDFC68A-C41A-4FB2-BDDB-7DB4895180F7Q27851705-D37EBC0E-6875-498D-874E-9A13E24B7B25Q27851987-5426760B-CB64-420D-B810-34F74F00F3FBQ28072513-F5690599-59E2-48F4-9677-D12227A29B90Q29547693-87869B98-7D21-4E06-8CFD-9A99D3A3C3F4Q29547695-A1E6B761-DEFA-482F-B880-56E3220B4B0BQ29616828-16733CD6-53CD-476B-B8D4-A877FC312B08Q30318240-67F81D86-08C1-408D-B867-0F91C145A5E8Q30423880-9B87BFD0-AF61-4125-B4E9-AE30910F59FDQ30500245-81751C56-1BE7-48E6-BB62-D03D1F297508Q30758991-024C5AAE-FD6B-459C-B895-AAADAFD146C8Q33284158-9DCC2BD8-B8B8-4A08-A37C-BC0E8AD1D173Q33388617-F8C73A0B-D094-4CF4-9758-FF192AFE7529Q33468432-D576A40F-A19C-4B7A-B696-04D6E87A0642Q33528957-5F32B801-BE38-435F-96FC-EB16643B19BCQ33561588-A0398A56-A241-4100-8F46-1E7AA5D7C78CQ33575434-BC1466E3-C56F-4D86-A7C2-A2342BA4C077Q33585060-8245216A-69C7-4983-AD60-29FD1BF75FB7Q33599144-C77CD2B0-9551-4F04-8685-45125880D495Q33601653-C87DCE09-D54A-464A-8730-CBFD2DF946C4Q33626569-309BB984-90DE-47C7-ABBE-75F92E81E363Q33629947-3985C829-28C2-471C-A039-C5812EA96F61Q33646338-B1770FC2-3638-4536-AA32-219684B3DAC6Q33648150-A0346993-E207-4CD7-879B-2DC2A90C4403Q33683001-80AFABA0-4354-41D1-81E4-4FCB34FEABFBQ33699124-192C5E82-95F4-43ED-AB4A-718F6C31C383Q33709284-5A48F996-C5AD-414B-B2EA-240835CC6F6AQ33713239-DC8FF053-D253-4BC2-9294-478218F3FAB5Q33731278-7AC896C0-CB34-4119-88BE-635CB0B3DF5FQ33750719-91F9FC83-D19D-43BA-8CAA-42FE0BEFE5AEQ33767497-C7E839A5-6D5F-4EA1-B030-C88C1DADE0A2Q33774262-45438F34-F399-4D14-9601-A4AF6C594094Q33777427-51249484-178C-497A-8F29-EE0AF9FA8517
P2860
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Activity of the dual kinase in ...... b-treated breast cancer cells.
@en
type
label
Activity of the dual kinase in ...... b-treated breast cancer cells.
@en
prefLabel
Activity of the dual kinase in ...... b-treated breast cancer cells.
@en
P2093
P1433
P1476
Activity of the dual kinase in ...... b-treated breast cancer cells.
@en
P2093
Barry R Keith
David W Rusnak
Dennis J Slamon
Glenn Spehar
Gottfried E Konecny
Guorong Yang
Karl C Podratz
Mark Berger
Mark D Pegram
Martina Rahmeh
P304
P356
10.1158/0008-5472.CAN-05-1182
P407
P577
2006-02-01T00:00:00Z